Loading clinical trials...
Loading clinical trials...
Freder1k-Study - Identification of Infants With Increased Type 1 Diabetes Risk for Enrollment Into Primary Prevention Trials
The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.
Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
Yes
Institut für Diabetesforschung, Helmholtz Zentrum München
Munich, Germany
Start Date
October 19, 2017
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
December 17, 2024
1,000,000
ESTIMATED participants
Lead Sponsor
Helmholtz Zentrum München
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions